| [1] |
Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma[J]. J Hepatol, 2023, 79(2): 506-515.DOI: 10.1016/j.jhep.2023.03.003.
|
| [2] |
Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies[J]. Nat Rev Drug Discov, 2022, 21(7): 495-508.DOI: 10.1038/s41573-021-00259-5.
|
| [3] |
Sun Y, Zhang Z, Jia K, et al. Autoimmune-related adverse events induced by immune checkpoint inhibitors[J]. Curr Opin Immunol, 2025, 94: 102556.DOI: 10.1016/j.coi.2025.102556.
|
| [4] |
Adashek JJ, Moran JA, Le DT, et al. Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly[J]. Cancer Metastasis Rev, 2025, 44(2): 43.DOI: 10.1007/s10555-025-10260-8.
|
| [5] |
Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017, 35(7): 785-792.DOI: 10.1200/JCO.2015.66.1389.
|
| [6] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.DOI: 10.1016/S0140-6736(17)31046-2.
|
| [7] |
Allaf ME, Kim SE, Master V, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2024, 25(8): 1038-1052.DOI: 10.1016/S1470-2045(24)00211-0.
|
| [8] |
Lee SM, Schulz C, Prabhash K, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study[J]. Lancet, 2023, 402(10400): 451-463.DOI: 10.1016/S0140-6736(23)00774-2.
|
| [9] |
Galsky MD, Arija JÁA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2020, 395(10236): 1547-1557.DOI: 10.1016/S0140-6736(20)30230-0.
|
| [10] |
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723.DOI: 10.1056/NEJMoa1003466.
|
| [11] |
Aamdal E, Jacobsen KD, Straume O, et al. Ipilimumab in a real-world population: a prospective Phase Ⅳ trial with long-term follow-up[J]. Int J Cancer, 2022, 150(1): 100-111.DOI: 10.1002/ijc.33768.
|
| [12] |
Ascierto PA, Del Vecchio M, Mackiewicz A, et al. Overall survival at 5 years of follow-up in a phase Ⅲ trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma[J]. J Immunother Cancer, 2020, 8(1): e000391.DOI: 10.1136/jitc-2019-000391.
|
| [13] |
Lee E, Jang JY, Yang J. Uncommon adverse events of immune checkpoint inhibitors in small cell lung cancer: a systematic review of case reports[J]. Cancers, 2024, 16(10): 1896.DOI: 10.3390/cancers16101896.
|
| [14] |
Liu C, Li M, Liu X, et al. Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis[J]. Front Immunol, 2024, 15: 1467306.DOI: 10.3389/fimmu.2024.1467306.
|
| [15] |
Amoroso V, Gallo F, Alberti A, et al. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies[J]. ESMO Open, 2023, 8(2): 100787.DOI: 10.1016/j.esmoop.2023.100787.
|
| [16] |
Abe H, Endo K, Kuroda H, et al. Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab[J]. Clin J Gastroenterol, 2024, 17(2): 307-310.DOI: 10.1007/s12328-023-01901-y.
|
| [17] |
Kimball K, Elad V, Hamad EJ, et al. Adult-onset T-cell acute lymphoblastic lymphoma-leukemia presenting with petechial rash: a case report[J]. Cureus, 2024, 16(8): e67744.DOI: 10.7759/cureus.67744.
|
| [18] |
Koga H, Tsutsumi M, Teye K, et al. Epitope spreading in immune checkpoint inhibitor-associated bullous pemphigoid[J]. JAMA Dermatol, 2025, 161(5): 557-559.DOI: 10.1001/jamadermatol.2024.6665.
|
| [19] |
Yang Y, Yu Q, Zhang H, et al. Restoring tumor antigenicity activates the “bystander” T cell immune cycle[J]. J Control Release, 2025, 380: 256-268.DOI: 10.1016/j.jconrel.2025.01.094.
|
| [20] |
Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses[J]. Sci Transl Med, 2021, 13(581): eabd8636.DOI: 10.1126/scitranslmed.abd8636.
|
| [21] |
Nishimura K, Konishi T, Ochi T, et al. CD21 lo B cells could be a potential predictor of immune-related adverse events in renal cell carcinoma[J]. J Pers Med, 2022, 12(6): 888.DOI: 10.3390/jpm12060888.
|
| [22] |
Li S, Xu D, Murakoshi N, et al. Autoantibody profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study[J]. Front Immunol, 2024, 15: 1423622.DOI: 10.3389/fimmu.2024.1423622.
|
| [23] |
Huang YT, Chen YP, Lin WC, et al. Immune checkpoint inhibitor-induced myasthenia gravis[J]. Front Neurol, 2020, 11: 634.DOI: 10.3389/fneur.2020.00634.
|
| [24] |
|
| [25] |
Gergely TG, Kucsera D, Tóth VE, et al. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment[J]. Br J Pharmacol, 2023, 180(6): 740-761.DOI: 10.1111/bph.15984.
|
| [26] |
Phillips GS, Wu J, Hellmann MD, et al. Treatment outcomes of immune-related cutaneous adverse events[J]. J Clin Oncol, 2019, 37(30): 2746-2758.DOI: 10.1200/JCO.18.02141.
|
| [27] |
Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors[J]. Cancer Sci, 2020, 111(5): 1468-1477.DOI: 10.1111/cas.14363.
|
| [28] |
Bass AR, Abdel-Wahab N, Reid PD, et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis[J]. Ann Rheum Dis, 2023, 82(7): 920-926.DOI: 10.1136/ard-2023-223885.
|
| [29] |
Curkovic NB, Irlmeier R, Bai X, et al. Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade[J]. Oncoimmunology, 2025, 14(1): 2494433.DOI: 10.1080/2162402X.2025.2494433.
|
| [30] |
Schwarzlmueller P, Triebig A, Assié G, et al. Steroid hormones as modulators of anti-tumoural immunity[J]. Nat Rev Endocrinol, 2025, 21(6): 331-343.DOI: 10.1038/s41574-025-01102-2.
|
| [31] |
Andrews MC, Duong CPM, Gopalakrishnan V, et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade[J]. Nat Med, 2021, 27(8): 1432-1441.DOI: 10.1038/s41591-021-01406-6.
|
| [32] |
Zeriouh M, Raskov H, Kvich L, et al. Checkpoint inhibitor responses can be regulated by the gut microbiota-A systematic review[J]. Neoplasia, 2023, 43: 100923.DOI: 10.1016/j.neo.2023.100923.
|
| [33] |
Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018, 24(12): 1804-1808.DOI: 10.1038/s41591-018-0238-9.
|
| [34] |
Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients[J]. Science, 2021, 371(6529): 595-602.DOI: 10.1126/science.abf3363.
|
| [35] |
Abu-Sbeih H, Faleck DM, Ricciuti B, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease[J]. J Clin Oncol, 2020, 38(6): 576-583.DOI: 10.1200/JCO.19.01674.
|
| [36] |
Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders[J]. J Clin Oncol, 2018, 36(19): 1905-1912.DOI: 10.1200/JCO.2017.77.0305.
|
| [37] |
Ghosh N, Reid P, Aude CA, et al. Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis[J]. RMD Open, 2023, 9(2): e003012.DOI: 10.1136/rmdopen-2023-003012.
|
| [38] |
Kidawara Y, Kadoya M, Kakutani-Hatayama M, et al. A case in which HLA-DR4 is involved in the development of complex immune-related endocrinological adverse events following combination therapy with nivolumab and ipilimumab[J]. Case Rep Endocrinol, 2024, 2024: 4662803.DOI: 10.1155/2024/4662803.
|
| [39] |
Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma[J]. J Immunother Cancer, 2015, 3: 39.DOI: 10.1186/s40425-015-0081-1.
|
| [40] |
Unger JM, Vaidya R, Albain KS, et al. Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials[J]. J Clin Oncol, 2022, 40(13): 1474-1486.DOI: 10.1200/JCO.21.02377.
|
| [41] |
Alves Costa Silva C, Almonte AA, Zitvogel L. Oncobiomics: leveraging microbiome translational research in immuno-oncology for clinical-practice changes[J]. Biomolecules, 2025, 15(4): 504.DOI: 10.3390/biom15040504.
|
| [42] |
Singh A, Mazumder A, Das S, et al. Harnessing the power of probiotics: boosting immunity and safeguarding against various diseases and infections[J]. Recent Adv Antiinfect Drug Discov, 2025, 20(1): 5-29.DOI: 10.2174/0127724344308638240530065552.
|
| [43] |
De Giglio A, Aprile M, Di Federico A, et al. Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC)[J]. Int J Mol Sci, 2022, 23(18): 10292.DOI: 10.3390/ijms231810292.
|
| [44] |
Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Cancers, 2020, 12(3): 546.DOI: 10.3390/cancers12030546.
|
| [45] |
van Not OJ, Verheijden RJ, van den Eertwegh AJM, et al. Association of immune-related adverse event management with survival in patients with advanced melanoma[J]. JAMA Oncol, 2022, 8(12): 1794-1801.DOI: 10.1001/jamaoncol.2022.5041.
|